Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors
Objective to study the safety and preliminary efficacy of intratumoral injection of CAR-T cells in the treatment of advanced liver tumors.
Hepatocellular Carcinoma , Cholangiocarcinoma
BIOLOGICAL: anti-GPC3 CAR-T cells
Adverse events attributed to the administration of the anti-GPC3 CAR-T cells, 2 years
Objective response rate (ORR), 2 years|Overall survival (OS), 2 years
Objective to study the safety and preliminary efficacy of intratumoral injection of CAR-T cells in the treatment of advanced liver tumors.